Cargando…

Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer

BACKGROUND: A patient's medical history and familial cancer history are important information for assessing the risk of hereditary cancer. We have generated a self-administered questionnaire for patients with gynecologic cancer. This pilot study analyzed the usefulness of this questionnaire and...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Kenta, Hirasawa, Akira, Irie-Kunitomi, Haruko, Akahane, Tomoko, Ueki, Arisa, Kobayashi, Yusuke, Yamagami, Wataru, Nomura, Hiroyuki, Kataoka, Fumio, Tominaga, Eiichiro, Banno, Kouji, Susumu, Nobuyuki, Aoki, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421611/
https://www.ncbi.nlm.nih.gov/pubmed/28334914
http://dx.doi.org/10.1093/jjco/hyx019
_version_ 1783234612502200320
author Masuda, Kenta
Hirasawa, Akira
Irie-Kunitomi, Haruko
Akahane, Tomoko
Ueki, Arisa
Kobayashi, Yusuke
Yamagami, Wataru
Nomura, Hiroyuki
Kataoka, Fumio
Tominaga, Eiichiro
Banno, Kouji
Susumu, Nobuyuki
Aoki, Daisuke
author_facet Masuda, Kenta
Hirasawa, Akira
Irie-Kunitomi, Haruko
Akahane, Tomoko
Ueki, Arisa
Kobayashi, Yusuke
Yamagami, Wataru
Nomura, Hiroyuki
Kataoka, Fumio
Tominaga, Eiichiro
Banno, Kouji
Susumu, Nobuyuki
Aoki, Daisuke
author_sort Masuda, Kenta
collection PubMed
description BACKGROUND: A patient's medical history and familial cancer history are important information for assessing the risk of hereditary cancer. We have generated a self-administered questionnaire for patients with gynecologic cancer. This pilot study analyzed the usefulness of this questionnaire and the rates of patients that meet the Society of Gynecologic Oncology criteria in ovarian cancer and endometrial cancer patients. METHOD: Ovarian or endometrial cancer patients were recruited for this study. After informed consent was obtained, participants completed the questionnaire. Genetic risks were assessed from the data of each patient's questionnaire by Society of Gynecologic Oncology guideline. Clinical and pathological findings were compared between the genetic risk groups. RESULTS: A total of 105 patients were identified with ovarian cancer and 56 patients with endometrial cancer eligible for this study. According to the Society of Gynecologic Oncology guideline, of the 105 ovarian cancer patients, 25 patients (23%) had a 20–25% risk and three patients (2.9%) had a 5–10% risk of hereditary breast and ovarian cancer syndrome. A further 22 patients (21%) had a 5–10% risk of Lynch syndrome. Two patients (1.9%) met the Amsterdam criteria II. Of 56 endometrial cancer patients, 24 patients (42.9%) had a 5–10% risk of Lynch syndrome. The endometrial cancer patients with genetic risk of Lynch syndrome were younger (mean age: 47.79) at diagnosis compared to patients without a genetic risk of Lynch syndrome (mean age: 57.91). CONCLUSIONS: In this study, we were able to show that the newly designed questionnaire is a useful tool for evaluating cancer family history along with Society of Gynecologic Oncology criteria or Amsterdam criteria II. When considering the risk of Lynch syndrome for a patient with ovarian cancer, it is important to collect a second and third relative's family history.
format Online
Article
Text
id pubmed-5421611
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-54216112017-05-11 Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer Masuda, Kenta Hirasawa, Akira Irie-Kunitomi, Haruko Akahane, Tomoko Ueki, Arisa Kobayashi, Yusuke Yamagami, Wataru Nomura, Hiroyuki Kataoka, Fumio Tominaga, Eiichiro Banno, Kouji Susumu, Nobuyuki Aoki, Daisuke Jpn J Clin Oncol Original Article BACKGROUND: A patient's medical history and familial cancer history are important information for assessing the risk of hereditary cancer. We have generated a self-administered questionnaire for patients with gynecologic cancer. This pilot study analyzed the usefulness of this questionnaire and the rates of patients that meet the Society of Gynecologic Oncology criteria in ovarian cancer and endometrial cancer patients. METHOD: Ovarian or endometrial cancer patients were recruited for this study. After informed consent was obtained, participants completed the questionnaire. Genetic risks were assessed from the data of each patient's questionnaire by Society of Gynecologic Oncology guideline. Clinical and pathological findings were compared between the genetic risk groups. RESULTS: A total of 105 patients were identified with ovarian cancer and 56 patients with endometrial cancer eligible for this study. According to the Society of Gynecologic Oncology guideline, of the 105 ovarian cancer patients, 25 patients (23%) had a 20–25% risk and three patients (2.9%) had a 5–10% risk of hereditary breast and ovarian cancer syndrome. A further 22 patients (21%) had a 5–10% risk of Lynch syndrome. Two patients (1.9%) met the Amsterdam criteria II. Of 56 endometrial cancer patients, 24 patients (42.9%) had a 5–10% risk of Lynch syndrome. The endometrial cancer patients with genetic risk of Lynch syndrome were younger (mean age: 47.79) at diagnosis compared to patients without a genetic risk of Lynch syndrome (mean age: 57.91). CONCLUSIONS: In this study, we were able to show that the newly designed questionnaire is a useful tool for evaluating cancer family history along with Society of Gynecologic Oncology criteria or Amsterdam criteria II. When considering the risk of Lynch syndrome for a patient with ovarian cancer, it is important to collect a second and third relative's family history. Oxford University Press 2017-05 2017-02-23 /pmc/articles/PMC5421611/ /pubmed/28334914 http://dx.doi.org/10.1093/jjco/hyx019 Text en © The Author 2017. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Article
Masuda, Kenta
Hirasawa, Akira
Irie-Kunitomi, Haruko
Akahane, Tomoko
Ueki, Arisa
Kobayashi, Yusuke
Yamagami, Wataru
Nomura, Hiroyuki
Kataoka, Fumio
Tominaga, Eiichiro
Banno, Kouji
Susumu, Nobuyuki
Aoki, Daisuke
Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer
title Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer
title_full Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer
title_fullStr Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer
title_full_unstemmed Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer
title_short Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer
title_sort clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421611/
https://www.ncbi.nlm.nih.gov/pubmed/28334914
http://dx.doi.org/10.1093/jjco/hyx019
work_keys_str_mv AT masudakenta clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer
AT hirasawaakira clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer
AT iriekunitomiharuko clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer
AT akahanetomoko clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer
AT uekiarisa clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer
AT kobayashiyusuke clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer
AT yamagamiwataru clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer
AT nomurahiroyuki clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer
AT kataokafumio clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer
AT tominagaeiichiro clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer
AT bannokouji clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer
AT susumunobuyuki clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer
AT aokidaisuke clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer